First AD

Second AD

Treatment Goals and Guidelines for CSU

Video content above is prompted by the following:

What are the factors that shape the development of treatment goals, both for patients and physicians?

What do international guidelines currently recommend for therapeutic approach? (

Patients with insufficient response, updosing should be considered, via shortening interview and/or increasing dosage

Second-line treatment: omalizumab; start with 300 mg/4 weeks

General recommendation to step-up and step-down treatment based on levels of disease control

Peer Exchange: Evolving Perspectives and Treatment Strategies in Chronic Spontaneous Urticaria 

HCPLive® Peer Exchange panel discussions feature authoritative insights, opinions, and perspectives on important issues facing today's care professionals.

Peer Exchange

Treatment goals for patients and physicians are influenced by various factors, including disease severity, patient preferences, and clinical guidelines. International guidelines recommend a structured therapeutic approach, starting with antihistamines as the first-line treatment. If patients exhibit an insufficient response, clinicians should consider updosing by either shortening the interval or increasing the dosage. Omalizumab is recommended as the second-line treatment, starting at 300 mg every four weeks, followed by cyclosporine as the third-line option. Treatment adjustments should be made based on disease control levels.

Panelists discuss the factors influencing the development of treatment goals for chronic spontaneous urticaria (CSU) from both patient and physician perspectives, highlighting current international guidelines that recommend antihistamines as first-line treatment, with options for updosing, and outlining second-line therapies such as omalizumab and third-line options like cyclosporine, along with the recommendation to adjust treatment based on disease control levels.